(CercleFinance.com) – AB Science SA announces today that its phase III clinical study (AB21004) in mild to moderate Alzheimer’s disease has been approved by the US Food and Drug Administration (FDA).
This decision follows similar authorizations received from several European countries, including the French Medicines Agency (ANSM).
For Professor Olivier Hermine, president of the scientific committee of AB Science and member of the Academy of Sciences, ‘the authorization to launch this confirmatory study issued by the main agencies
international health shows that masitinib is considered a credible drug candidate in Alzheimer’s disease in the largest population and therefore strategically the most important’
‘Based on its mechanism of action, we believe that masitinib
could act on the evolution of the disease”, concludes the specialist.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
